A patient journey is more than a subscription
Telehealth delivers some clinical interactions remotely. Direct-to-consumer healthcare describes a route to the customer and can combine consultations, subscriptions, medication and other services. These terms are not interchangeable business models. A consumer paying for a condition-specific program creates different economics from an employer purchasing access for a covered population.
Separate clinical and commercial units
A consultation, paying subscriber, covered member and prescription are different units. Comparing companies on a generic user count can conceal differences in utilization and payment. Hims & Hers and Teladoc should therefore not be modeled as if they sell an identical subscription with the same customer-acquisition and fulfillment requirements.
A useful comparison identifies who pays, what service is included and when revenue is earned. Enterprise access can generate revenue without every covered person using a consultation. A consumer medication program can require continuing fulfillment and clinical support. Those differences matter to both retention and gross profit.
GLP-1 availability and compounding
The FDA's policy updates explain that shortage status and statutory conditions affect compounding exemptions. A previous shortage does not establish an unlimited continuing right to mass-market copies. The applicable product, circumstances and current policy must be identified rather than assumed from historical availability.
The FDA's announced enforcement position is relevant to the commercial risk. An announcement should be distinguished from a new enacted statute or a final determination about every individual prescription. This guide does not claim that every compounded medicine is unlawful or treat a proposal as completed law.
Acquisition and retention economics
Consumer marketing can create rapid initial demand while obscuring the cost of retaining a patient. An acquisition model should account for the clinical evaluation, refunds, support and fulfillment required to deliver the service. Advertising efficiency in one condition or channel may not transfer to another.
Repeat revenue depends on continued clinical appropriateness, affordability and patient use. A subscriber who pauses or discontinues treatment changes the economic profile. Subscription revenue is therefore not automatically permanent, and a higher initial order value may be less attractive if it comes with substantial acquisition expense or short persistence.
Channel concentration also matters. A company depending on one advertising source can face rising acquisition costs without any change in clinical demand. Retention and contribution after acquisition expense should be assessed for comparable customer cohorts, rather than inferred from the growth of total visits or a single quarter of new subscribers.
Clinical execution and retention constrain scale
The bottleneck can be trustworthy clinical delivery rather than the video interface. Appropriate assessment, escalation, prescribing, pharmacy coordination and follow-up must work together. A platform that improves access still needs a service model capable of handling patients whose needs exceed a standardized remote workflow.
For investment analysis, separate medical-service revenue from medication and other product revenue where disclosures permit. Gross margin differences can reflect mix rather than superior technology. A company's broad revenue growth does not establish that a particular condition-specific offering is profitable or resilient to changes in product supply.
Risks and disconfirming evidence
Regulatory changes, clinical quality failures, medication availability and rising marketing costs can affect growth. Dependence on one treatment category can concentrate risk even when the customer base is large. The thesis weakens when retention depends on a temporary supply situation or when service quality deteriorates with scale. Durable value requires reliable care delivery and transparent unit economics rather than a simple extrapolation of online traffic into prescriptions.